Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons

HIV Clinical Trials

Volumn 5, Issue 6, 2004, Pages 416-433

  Fichtenbaum, Carl J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

CHD management; Coronary heart disease; HAART; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; C REACTIVE PROTEIN; CALCIUM; CYTOCHROME P450; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG METABOLISM; DRUG SUBSTITUTION; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID BLOOD LEVEL; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE;

ALGORITHMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY ARTERIOSCLEROSIS; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; PRACTICE GUIDELINES; RISK FACTORS;

EID: 13844254117     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/P07M-HNT8-L08G-5TKU     Document Type: Review

References (115)

1. Bonnet F, Morlat P, Chêne G, et al., for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GESCA). Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med. 2002;3:195-199.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
4. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
5. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium. 2000;7:223-242.
6. Mauss S. HIV-associated and antiretroviral-induced hyperlipidaemia: an update. J HIV Ther. 2003;8:29-31.
7. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11:938-939.
8. Henry K, Melroe H, Huebusch J, et al. Severe premature coronary artery disease with protease inhibitors [letter]. Lancet. 1998;351:1328.
9. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351:1959.
10. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis [letter]. Clin Infect Dis. 1999;28:161-162.
11. Jütte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment. [letter] AIDS. 1999;13:1796-1797.
12. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet. 1998;351:1958-1959.
13. Friis-Møller N, Weber R, Reiss P, et al, for the DAD Study Group. Cardiovascular disease risk factors in HIV-infected persons - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
14. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Hariawala MD, Deshmukh VV, Sellke FW. Insulin resistance: a common factor in the triad of dyslipidemia, hypertension, and coronary artery disease? Am J Med Sci. 1997;313:104-106.
17. Dubé MP, Stein JH, Aberg JA, et al, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627
18. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
19. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. July 14, 2003. Available at: http://AIDSinfo.nih.gov. Accessed August 23, 2003.
20. Hulley SB. The US National Cholesterol Education Program. Adult treatment guidelines. Drugs. 1988;36(suppl 3):100-104.
21. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986; 256:2835-2838.
22. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 2001;87(suppl 5A):2B-7B.
23. Assmann G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol. 1992;70:10H-13H.
24. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis. 2001;159:201-208.
25. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423-1427.
26. Shor-Posner G, Basit A, Lu Y, et al. Hypercholesterolemia is associated with immune dysfunction in early human immunodeficiency vinus-1 infection. Am J Med. 1993; 94:515-519.
27. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289: 2978-2982.
28. Barbarini G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS. 2003;17(suppl 1):S46-50.
29. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS. 2003;17(suppl 1):S12-20.
30. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1037-1043.
31. Wang TJ, Nam BH, D'Agostino RB, et al. Carotid intimamedia thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation. 2003;108:572-576.
32. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
33. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92:17K-22K.
34. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coronary Artery Dis. 2000;11:41-46.
35. Acevedo M, Sprecher DL, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV-infected persons: "a call for cardiovascular prevention". Atherosclerosis. 2002; 163:349-354.
36. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol. 1993;144:225-231.
37. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr. 1994;7:1149-1156.
38. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24:416-420.
39. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis. 2002;34:98-102.
40. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
41. Henry K, Zackin R, Dube M, Hammer S, Sprecher D, Currier J, for the ACTG 50561372A Team. ACTG 5056: C-reactive protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1 infected persons durably suppressed on an indinavir (IDV)-containing regimen. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 694-T.
42. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
43. Hsue PY, Kamini G, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:316-319.
44. Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial infarction in patients with human immunodeficiency virus. Am Heart J. 2004;147:55-59.
45. Holmberg SD, Moorman AC, Williamson JM, et al, HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.
46. Law M, Friis-Møller N, Weber R, et al, for the DAD Study Group. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003;4:1-10.
47. Law M, D'Arminio Monforte A, Friis-Moller N, et al. Cardio- and cerebrovascular events (CVE) and predicted rates of myocardial infarction (MI) in the DAD study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 737.
48. Rickerts V, Brodt H-R, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-Cohort Study. Eur J Med Res. 2000;5:329-333.
49. Iloeje U, Yuan Y, L'Italien G et al. Protease inhibitor (PIs) exposure time and risk of cardiovascular disease (CHD) in human immunodeficiency virus (HIV) infected patients. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 736.
50. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
51. Klein D, Hurley L, Queensbury C, et al. Hospitalization for coronary heart disease and myocardial infarction among men with HIV-1 infection: follow-up through 12/31/03. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 739.
52. Jacoby DS, Mohler III ER, Rader DJ. Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep. 2004;6:20-26.
53. Currier J, Kendall M, Henry K, et al. Carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 131.
54. Hsue P, Lo J, Franklin A, Bolger AF, Deeks SG, Waters DD. Increased atherosclerotic progression in patients with HIV: the role of traditional and immunological risk factors. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 139Ib.
55. Meng Q, Lima JAC, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J. 2002;144:642-648.
56. Talwani R, Falusi OM, Mendes de Leon CF, et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:191-195.
57. Torre D, Pugllese A, Orofino G. Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in patients with HIV-1 infection. Clin Infect Dis. 2002;35:631-632.
58. Levy AR, Iloeje U, Hogg RS, et al. Increases in blood cholesterol and triglycerides among persons with HIV/AIDS on highly active antiretroviral therapy compared with population norms. Antivir Ther. 2003;8:L48. Abstract 66.
59. Danner SA, Carr A, Leonard JM, et al, for the European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528-1533.
60. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
61. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700-705.
62. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:1-9.
63. Dubé MP, Qian D, Edmondson-Melangon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475-481.
64. Walmsley S, Bernstein B, King M, et al, for the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
65. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-1774.
66. Koppel K, Bratt G, Eriksson M, Sandström E. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11:451-455.
67. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
68. Fisac C, Fumero E, Crespo M, et al. Metabolic changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz or nevirapine: 24 month results of a randomized study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Abstract 78.
69. Markowitz M, Simon V, Vasan S, et al. 48-week results of an atazanavir-based QD regimen in patients switching from BID-based HAART. Antivir Ther. 2003;8(suppl 1):S329. Abstract 543.
70. Murphy R, Pokrovsky V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 555.
71. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, for the AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
72. Mulligan K, Grunfeld C, Tal VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
73. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
74. Bruno R, Gazzaruso C, Sacchi P, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk [letter]. J Acquir Immune Defic Syndr. 2002;31:363-365.
75. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-F173.
76. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CHD risk. Diabetes Res Clin Pract. 2003;61 (suppl 1):S9-S18.
77. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:11-18.
78. Dube M, Zackin R, Parker R, et al, Prospective study of glucose and lipid metabolism in antiretroviral naïve subjects randomized to receive nelfinavir, efavirenz or both combined with zidovudine + lamivudine (ZDV+3TC) or didanosine + stavudine: A5005s, a substudy of ACTG 384. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Abstract 74.
79. Sension M, Thiry A, Giordano M, for the AI424-034 International Study Team. Absence of insulin resistance through week 24 with atazanavir once-daily and efavirenz once-daily each with fixed-dose zidovudine plus lamivudine, Antivir Ther. 2002;7:L26. Abstract 36
80. Mascolini M. On the trail of fugitive fat: the chase turns to NRTIs. J Int Assoc Physicians AIDS Care 1999;5:24-43.
81. Vigouroux C, Gharakhanian S, Salhi Y, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 1999;25:383-392.
82. Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis. 2003;45:305-318.
83. Staszewski S, Gallant JE, Pozniak AL, et al, for the 903 Study Team. Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Poster 564b.
84. Kumar P, Rodriguez- French A, Thompson M, et al. Prospective study of hyperlipidemia in ART-naïve subjects taking combivir /abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). In: Program and abstracts of the Ninth Conference on Retrovinuses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 33.
85. Fontas E, Van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
86. van der Valk M, Kastelein JJP, Murphy RL, et al, for the Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-2414.
87. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-999.
88. Simon GL, Liappis AP, Granger SL, et al. Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens. Antivir Ther. 2002;7:L9. Abstract 14.
89. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4:29-36.
90. van Leth F, Hassink E, Phanuphak P, et al, for the 2NN Study Group. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, with stavudine and lamivudine. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 176.
91. van Leth F, Phanuphak P, Gazzard B, et al, for the 2NN Study Group. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN study). In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Massachusetts. Abstract 752.
92. Shahmahesh M, das S, Stolinski M, et al. Insulin resistance and apolipoprotein B kinetics: a comparison of protease inhibitor, efavirenz, or nevirapine-containing antiretroviral regimens. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, California. Poster 704.
93. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-1230.
94. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002;16:1383-1389.
95. Gil P, Górgolas M, Estrada V, et al. Efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected persons with undetectable viral load: results after 3 years. In: Program and abstracts of the Second International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 590.
96. Martinez E, Arnaiz JA, Podzamczer D, et al, for the Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-1046.
97. Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a PI-containing regimen to Abacavir, Efavirenz or Nevirapine. 12 month results of a randomized study (LIPNEFA). In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract ThPE7354.
98. Martinez E, Podzamczer E, Ribera P, et al. Switching protease inhibitors to nevirapine, efavirenz or abacavir: a randomized, multicenter, open-label, simplification trial. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract WeOrB1262.
99. Fichtenbaum CJ. The evaluation and management of dyslipidemia in HIV-infected patients. AIDS Clin Care. 2001;13:113-117, 120.
100. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS 2001;15:1503-1508.
101. Stein JH, Wu Y, Kawabata H, Iloeje UH. Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol. 2003;92:270-274.
102. Stein EA The power of statins: aggressive lipid lowering. Clin Cardiol. 2003;26(4 suppl 3):III25-III31.
103. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al., NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS. 2002;16:569-577.
104. Hsyu PH, Lewis RH, Schultz MD, Lillibridge JH, Kerr BM. Pharmacokinetic interactions between nelfinavir and two HMG-CoA reductase inhibitors simvastatin and atorvastatin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Ontario, Canada. Abstract 425.
105. Schuster H. Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology. 2003;99:126-139.
106. Carr RA, Andre AK, Bertz RJ, Hsu A, Lam W, Chang M. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Ontario, Canada. Abstract 1644.
107. Gerber JG, Fichtenbaum CJ, Rosenkranz S, et al. Efavirenz (EFV) is a significant inducer of simvastatin (SIM) and atorvastatin (ATR) metabolism: results of ACTG A5108 study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract L-3.
108. Narayan S, Hawley N, Giguère P, Badley AD. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials. 2003;4:164-169.
109. Aberg JA, Zackin RA, Evans SR, et al., and ACTG 5087 Team. A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate (F) versus pravastatin (P) in HIV-infected subjects with lipid abnormalities: final results of ACTG 5087. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract N-53.
110. Calza L, Manfredi R, Chiodo F. Dyslipidemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrobial Chemother. 2004;53:10-14.
111. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352:1031-1032.
112. Manfredi R, Calza L, Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS. 2003:17:851-859.
113. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS. 1999;13:868-869.
114. Caramelli B, de Bernoche CY, Sartori AM, et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis. 2001;5:332-338.
115. Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38:562-568.